Topics: Business enterprise

Sigrid enters exclusive global licensing and research collaboration to commercialize SiPore® in consumer-oriented oral health

21 January 2026 00:00

Stockholm — January 21, 2026 — Sigrid Therapeutics (Sigrid) is a Swedish-based, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence , developed to support weight loss by reducing appetite and sugar cravings while promoting fat loss and preserving muscle mass , and Glucose Stabi

SIGRID Stabiliser – Record online sales at Kronans Apotek lead to store launch this fall

27 August 2025 00:00

After an exceptionally successful online launch earlier this year, Sigrid Therapeutics and Kronans Apotek are now ready to take the next step: SIGRID Stabiliser will be launched on store shelves across the country in the fall of 2025.

SIGRID's Glucose Stabiliser demonstrates clinical efficacy and strong sales growth in the US – meeting growing global demand for natural solutions for metabolic health

9 June 2025 00:00

SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser.

Sigrid enters strategic partnership with GetHealthy to meet growing demand in the US for Glucose Stabiliser as a non-pharmaceutical solution to control blood sugar levels

2 September 2024 00:00

Sigrid Therapeutics today announced the signing of a strategic partnership with GetHealthy.store, a leading US provider of e-commerce solutions for healthcare providers selling healthcare and nutritional products.

Sigrid Therapeutics launches Glucose Stabiliser in the US, an over-the-counter dietary supplement designed to control blood sugar and body weight

14 November 2023 00:00

Sigrid Therapeutics today announced that the company has launched Glucose Stabiliser in the US.

Sigrid Therapeutics secures SEK 44 million in oversubscribed financing round targeting the growing market for the treatment of obesity and diabetes

31 October 2023 00:00

Sigrid Therapeutics has secured SEK 44 million in a successful and oversubscribed financing round, underscoring the strong confidence of investors in Sigrid's innovative SiPore technology®.

Sigrid Therapeutics appoints Professor Iain Chapple, an international authority in oral health, to the company's Scientific Advisory Board

9 May 2023 00:00

Sigrid Therapeutics (Sigrid), a Swedish consumer healthcare company, announced today that Professor Iain Chapple, a world-leading expert in oral health from the University of Birmingham's College of Medical and Dental Sciences, has been appointed as the company's scientific advisor.

Sigrid Therapeutics reports positive results from consumer testing of SiPore®, a product intended for prediabetics, type 2 diabetics and obese people to control blood sugar levels

8 March 2023 00:00

Sigrid Therapeutics, an innovative, consumer-focused health company, today presented the results of a consumer trial ahead of the launch of their clinically proven SiPore® technology for blood sugar control in prediabetics and type 2 diabetics.

Sigrid Therapeutics raises additional SEK 10.6 million in oversubscribed rights issue to accelerate commercialization of SiPore®

16 January 2023 10:19

Sigrid Therapeutics, a Swedish consumer-focused technology company in consumer health, announced today that an additional SEK 10.6 million has been added to the company to accelerate the commercialization of its portfolio of dietary supplements based on SiPore®.

Sigrid Therapeutics appoints Mattias Ankerberg, an international leader from the consumer goods industry, as Chairman

24 October 2022 00:00

Sigrid Therapeutics, a Swedish consumer healthcare technology company, today announced that it has appointed Mattias Ankerberg as Chairman of the Board.

Sigrid Therapeutics aims for the consumer market – offers free testing of scientifically proven product against diabetes and obesity ahead of launch

16 May 2022 00:00

Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® .

Sigrid Therapeutics takes in SEK 72 million in new capital

10 November 2021 00:00

Swedish healthtech startup Sigrid Therapeutics is on its way to preventing two of the world's biggest health challenges, type 2 diabetes and obesity, with its SiPore15® powder.

Sigrid Therapeutics' silica-based biomaterial SiPore15 [® ] granted US patent for treatment and prevention of obesity and overweight

1 July 2020 00:00

Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).

Technology company Sigrid Therapeutics closes oversubscribed rights issue of SEK 15.5 million to accelerate market approval for groundbreaking blood sugar lowering product

5 September 2019 00:00

Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces that it has closed a rights issue of SEK 15.5 million.

All patients treated in Sigrid Therapeutics' STAR clinical trial

16 July 2019 00:00

Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.